Suppr超能文献

优化针对耐药结核分枝杆菌的联合治疗:一项建模研究。

Optimizing combination therapy against drug resistance Mycobacterium tuberculosis: a modelling study.

作者信息

Helikumi Mlyashimbi, Daudi Salamida, Lusekelo Eva, Mushayabasa Steady

机构信息

Department of Mathematics and Statistics, College of Science and Technical Education, Mbeya University of Science and Technology, P.O. Box 131, Mbeya, Tanzania.

National Institute of Transport, Faculty of Informatics and Technical Education, Department of Education and Mathematics, P. O. Box 705, Dar-es-Salaam, Tanzania.

出版信息

J Biol Phys. 2025 Jun 6;51(1):20. doi: 10.1007/s10867-025-09685-7.

Abstract

Despite the prevalence of co-infection with drug-sensitive and drug-resistant Mycobacterium tuberculosis strains within a single host, the implications of such dual infections remain poorly understood. In this study, we develop a comprehensive within-host model that incorporates both bacterial strains, their mutation dynamics, and cross-reactive immune responses. We analyze the basic reproduction number ( ) and identify its dependence on key parameters, finding that is strongly influenced by the adaptive immune response rate, bacterial fitness cost, and macrophage engulfment rates. Our bifurcation analysis reveals the presence of a backward bifurcation at , indicating complex threshold dynamics. Utilizing optimal control theory, we evaluate treatment strategies and demonstrate that a combination therapy with at least 85% efficacy against both strains can effectively control the infection. These findings deepen our understanding of host-pathogen interactions in tuberculosis and provide valuable insights for the development of more effective anti-tuberculosis therapies.

摘要

尽管在单个宿主体内同时感染药物敏感型和耐药型结核分枝杆菌菌株的情况很普遍,但这种双重感染的影响仍知之甚少。在本研究中,我们开发了一个全面的宿主内模型,该模型纳入了两种细菌菌株、它们的突变动态以及交叉反应性免疫反应。我们分析了基本再生数( )并确定其对关键参数的依赖性,发现 受到适应性免疫反应率、细菌适应性成本和巨噬细胞吞噬率的强烈影响。我们的分岔分析揭示了在 处存在向后分岔,表明存在复杂的阈值动态。利用最优控制理论,我们评估了治疗策略,并证明对两种菌株均具有至少85%疗效的联合疗法可以有效控制感染。这些发现加深了我们对结核病中宿主 - 病原体相互作用的理解,并为开发更有效的抗结核疗法提供了有价值的见解。

相似文献

6
Cycloserine resistance among drug-resistant tuberculosis cases in Taiwan.台湾耐药结核病病例中的环丝氨酸耐药情况。
Microbiol Spectr. 2025 Jul;13(7):e0342224. doi: 10.1128/spectrum.03422-24. Epub 2025 Jun 9.

本文引用的文献

1
Efficacy and safety data on pretomanid for drug-resistant TB.用于耐药结核病的普瑞玛尼的疗效和安全性数据。
IJTLD Open. 2025 Feb 1;2(2):73-82. doi: 10.5588/ijtldopen.24.0360. eCollection 2025 Feb.
4
India marching towards TB elimination: How far we are.印度迈向结核病消除之路:我们已走多远。
Indian J Tuberc. 2024 Apr;71(2):213-218. doi: 10.1016/j.ijtb.2023.06.019. Epub 2023 Jun 29.
5
: immune response, biomarkers, and therapeutic intervention.免疫反应、生物标志物与治疗干预。
MedComm (2020). 2024 Jan 6;5(1):e419. doi: 10.1002/mco2.419. eCollection 2024 Jan.
7
Tuberculosis: current challenges and beyond.结核病:当前挑战及未来展望
Breathe (Sheff). 2023 Mar;19(1):220166. doi: 10.1183/20734735.0166-2022. Epub 2023 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验